EHA 2022 | Clinical characteristics of h-MDS
Enrico Attardi, MD, University of Rome Tor Vergata, Rome, Italy, discusses hypocellular myelodysplastic syndromes (h-MDS), a rare subgroup of MDS affecting 10-15% of patients with MDS, describing the results of a study which evaluated the clinical features, overall survival (OS), and treatment of h-MDS in comparison to patients with normal MDS. The study revealed that the immunological landscape of patients with h-MDS is characterized by T and NK cell expansion, which is more common in patients with high-risk (HR) h-MDS and low-risk (LR) h-MDS respectively. These findings could help personalize treatments in this patient population. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
